Phase 1 Non-small Cell Lung Cancer (NSCLC) trials recruiting now

All Non-small Cell Lung Cancer (NSCLC) trials, every phase

Other phases for Non-small Cell Lung Cancer (NSCLC)

Phase 1 Non-small Cell Lung Cancer (NSCLC) trials

• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
  NCT07172802 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
  NCT06754930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
  NCT06476808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
  NCT05473156 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
  NCT07540572 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 11 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  NCT07517198 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
  NCT05271916 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
  NCT06026410 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
  NCT07151040 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
  NCT07630961 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
  NCT07087223 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  NCT05799274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
  NCT06567015 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
  NCT07397338 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
  NCT06162221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06040541 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
  NCT07660055 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
  NCT05985655 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
  NCT06332755 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.